Semax + Selank common uses, half-life, side effects and more

Semax + Selank is a gray-market pairing of two Russian intranasal neuropeptides that people run together for focus and calm. Semax is the stimulating half that people use for mental stamina and drive. Selank is the calming half that people use to take the anxious edge off. People combine them so the focus from Semax is balanced by the anxiety control from Selank. Neither peptide is approved as a medicine outside Russia. The combination itself is not sold as an approved product anywhere. People outside Russia obtain it as gray-market nasal sprays, pre-mixed vials, or two separate reconstituted powders.

• Focus and mental stamina with less anxious edge than Semax alone
• Calm and stress resilience without heavy sedation
• Short nootropic courses during demanding cognitive work
• Steadier attention when anxiety would otherwise disrupt it

Once or twice daily in the morning

Common intranasal blend use is about 250 to 500 mcg of each peptide per administration. People take it once or twice daily in the morning. There is no blend-specific standard behind that number. Each peptide is run at its own standalone intranasal dose. Some first-hand reports run as high as 800 to 1,000 mcg of each per session. Per-spray delivery is not fixed and depends on the concentration and the pump. Selank stays within its usual range at these doses. Semax has a lower usual ceiling than Selank. A twice-daily blend at the upper end can push the daily Semax to around 1,000 mcg. That exceeds the 200 to 600 mcg most sources treat as normal. A Semax-heavy product raises the Semax exposure further. Injectable blend vials are also sold. No per-component subcutaneous blend dose is established. Injected use is set from each compound's own dose of about 100 to 300 mcg.

• Most blends pair equal amounts of each such as 5 mg Semax with 5 mg Selank
• One compounded product instead runs Semax heavier at a 3 to 1 ratio over Selank
• Every 1 mg drawn from a 1:1 vial delivers about 500 mcg Semax and 500 mcg Selank
• Some products sold as blends are two separate bottles rather than one mixed vial
• Separate bottles let Semax be timed earlier in the day and Selank later
• Users usually run short courses of a few weeks rather than dosing continuously

No combination pharmacokinetic study exists for Semax plus Selank. Both peptides clear from blood within minutes and break down into smaller fragments. Their effects can last for hours because the change happens downstream in the brain rather than in the blood.

• Nasal burning, irritation, dryness, or runny nose with intranasal use
• Headache, restlessness, agitation, or trouble sleeping from the Semax half
• Allergy symptoms or rash if Selank is not tolerated
• Injection-site redness, bruising, itching, or pain with subcutaneous use

• Semax

  250 to 500 mcg per intranasal blend administration

• Selank

  250 to 500 mcg per intranasal blend administration

Semax is a synthetic ACTH(4-10) analog without the hormonal effect of ACTH. Its direct receptor target is unsettled. Its clearer effects are downstream in the brain. It raises the growth factors BDNF and NGF and lifts dopamine and serotonin turnover in animals. Selank is a stabilized analog of the immune peptide tuftsin. It slows the enzymes that break down the body's own enkephalins. It also shifts GABA-system gene expression in a calming direction without binding the benzodiazepine site. People pair the two so Semax supplies alert focus while Selank reduces the anxious overstimulation that pure arousal can bring. The pairing is a mechanistic rationale rather than a tested effect.

No clinical trial has tested Semax plus Selank as a combined product. One human study gave Semax, Selank, and placebo separately to 52 healthy people and found brain-network changes partly specific to each compound. That points to distinct acute effects but does not test the two together. Semax on its own has modest Russian clinical evidence in stroke and cognition. Selank on its own has modest Russian clinical evidence in generalized anxiety. Both bodies of evidence are small, mostly open-label, and single-country. Most of the work comes from the group that developed the peptides rather than from independent labs. None of it has been replicated in the West. The blend rests on the two single-agent profiles and community practice rather than a tested stack.

• Gray-market Semax and Selank products can vary in identity, purity, strength, sterility, or pump-dose accuracy
• The Semax half can worsen insomnia, agitation, mania, psychosis, or severe anxiety because it is stimulating
• A 1:1 blend dosed twice daily delivers roughly 1,000 mcg of Semax a day and lands well above the amount Semax is normally used at
• Combining either peptide with stimulant, antidepressant, MAO-inhibitor, sedative, opioid, or serotonergic drugs deserves clinician review first
• Pregnancy, breastfeeding, childhood use, and long-term continuous use are unsafe because the safety data are too thin
• Autoimmune or active immune conditions warrant caution because Selank is a tuftsin analog with immune activity